Madrigal Pharmaceuticals, Inc. MDGL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s additional paid-in capital?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported additional paid-in capital of $2.73B in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s additional paid-in capital increased by 5.5% year-over-year, from $2.59B to $2.73B.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 32.3% compound annual growth rate (CAGR), from $665.39M to $2.69B.